{"pmid":32401847,"title":"The Heart and COVID-19: What Cardiologists Need to Know.","text":["The Heart and COVID-19: What Cardiologists Need to Know.","In face of the pandemic of the novel coronavirus disease 2019 (COVID-19), the management of patients with cardiovascular risk factors and/or disease is challenging. The cardiovascular complications evidenced in patients with COVID-19 derive from several mechanisms, ranging from direct viral injury to complications secondary to the inflammatory and thrombotic responses to the infection. The proper care of patients with COVID-19 requires special attention to the cardiovascular system aimed at better outcomes.","Arq Bras Cardiol","Costa, Isabela Bispo Santos da Silva","Bittar, Cristina Salvadori","Rizk, Stephanie Itala","Araujo Filho, Antonio Everaldo de","Santos, Karen Alcantara Queiroz","Machado, Theuran Inahja Vicente","Andrade, Fernanda Thereza de Almeida","Gonzalez, Thalita Barbosa","Arevalo, Andrea Nataly Galarza","Almeida, Juliano Pinheiro de","Bacal, Fernando","Oliveira, Glaucia Maria Moraes de","Lacerda, Marcus Vinicius Guimaraes de","Barberato, Silvio Henrique","Chagas, Antonio Carlos Palandri","Rochitte, Carlos Eduardo","Ramires, Jose Antonio Franchini","Kalil Filho, Roberto","Hajjar, Ludhmila Abrahao","32401847"],"abstract":["In face of the pandemic of the novel coronavirus disease 2019 (COVID-19), the management of patients with cardiovascular risk factors and/or disease is challenging. The cardiovascular complications evidenced in patients with COVID-19 derive from several mechanisms, ranging from direct viral injury to complications secondary to the inflammatory and thrombotic responses to the infection. The proper care of patients with COVID-19 requires special attention to the cardiovascular system aimed at better outcomes."],"journal":"Arq Bras Cardiol","authors":["Costa, Isabela Bispo Santos da Silva","Bittar, Cristina Salvadori","Rizk, Stephanie Itala","Araujo Filho, Antonio Everaldo de","Santos, Karen Alcantara Queiroz","Machado, Theuran Inahja Vicente","Andrade, Fernanda Thereza de Almeida","Gonzalez, Thalita Barbosa","Arevalo, Andrea Nataly Galarza","Almeida, Juliano Pinheiro de","Bacal, Fernando","Oliveira, Glaucia Maria Moraes de","Lacerda, Marcus Vinicius Guimaraes de","Barberato, Silvio Henrique","Chagas, Antonio Carlos Palandri","Rochitte, Carlos Eduardo","Ramires, Jose Antonio Franchini","Kalil Filho, Roberto","Hajjar, Ludhmila Abrahao"],"date":"2020-05-14T11:00:00Z","year":2020,"_id":"32401847","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.36660/abc.20200279","topics":["Treatment"],"weight":1,"_version_":1666865855070208001,"score":9.490897,"similar":[{"pmid":32336069,"title":"What should a cardiologist know about coronavirus disease 2019?","text":["What should a cardiologist know about coronavirus disease 2019?","Severe acute respiratory syndrome coronavirus 2 (SARSCoV2) is the cause of coronavirus disease 2019 (COVID19). The most common symptoms of COVID19 are: fever (81.8%-100%), cough (46.3%-86.2%), myalgia and fatigue (11%-50%), expectoration (4.4%-72%), and dyspnea (18.6%-59%). The most common laboratory abnormalities in COVID19 include decreased lymphocyte count (35%-82.1%), thrombocytopenia (17%-36.2%), elevated serum Creactive protein (60.7%-93%), lactate dehydrogenase (41%-76%), and Ddimer concentrations (36%-46.4%). Among comorbidities in patients with COVID19, cardiovascular disease is most commonly found. In addition, patients with concomitant cardiovascular diseases have worse prognosis and more often require admission to the intensive care unit (ICU), compared with patients without such comorbidities. It is estimated that about 20% of patients with COVID19 develop cardiac injury. Cardiac injury is more prevalent among patients with COVID19 who require ICU care. In a group of critically ill patients, 27.5% had an elevated Nterminal pro-Btype natriuretic peptide concentration, and increased cardiac troponin level was found in 10% of patients. One of the lifethreatening cardiac manifestations is coronavirus fulminant myocarditis, which may also occur without accompanying symptoms of pulmonary involvement. Early recognition and treatment is crucial in these cases. So far, data on the incidence of arrhythmias in patients with COVID19 are limited. Coronavirus disease 2019 impacts patients with cardiovascular comorbidities and affects daily practice of cardiologists. Thus, it is important to know typical COVID19 symptoms, possible clinical manifestations, complications, and recommended treatment.","Kardiol Pol","Slawinski, Grzegorz","Lewicka, Ewa","32336069"],"abstract":["Severe acute respiratory syndrome coronavirus 2 (SARSCoV2) is the cause of coronavirus disease 2019 (COVID19). The most common symptoms of COVID19 are: fever (81.8%-100%), cough (46.3%-86.2%), myalgia and fatigue (11%-50%), expectoration (4.4%-72%), and dyspnea (18.6%-59%). The most common laboratory abnormalities in COVID19 include decreased lymphocyte count (35%-82.1%), thrombocytopenia (17%-36.2%), elevated serum Creactive protein (60.7%-93%), lactate dehydrogenase (41%-76%), and Ddimer concentrations (36%-46.4%). Among comorbidities in patients with COVID19, cardiovascular disease is most commonly found. In addition, patients with concomitant cardiovascular diseases have worse prognosis and more often require admission to the intensive care unit (ICU), compared with patients without such comorbidities. It is estimated that about 20% of patients with COVID19 develop cardiac injury. Cardiac injury is more prevalent among patients with COVID19 who require ICU care. In a group of critically ill patients, 27.5% had an elevated Nterminal pro-Btype natriuretic peptide concentration, and increased cardiac troponin level was found in 10% of patients. One of the lifethreatening cardiac manifestations is coronavirus fulminant myocarditis, which may also occur without accompanying symptoms of pulmonary involvement. Early recognition and treatment is crucial in these cases. So far, data on the incidence of arrhythmias in patients with COVID19 are limited. Coronavirus disease 2019 impacts patients with cardiovascular comorbidities and affects daily practice of cardiologists. Thus, it is important to know typical COVID19 symptoms, possible clinical manifestations, complications, and recommended treatment."],"journal":"Kardiol Pol","authors":["Slawinski, Grzegorz","Lewicka, Ewa"],"date":"2020-04-28T11:00:00Z","year":2020,"_id":"32336069","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.33963/KP.15302","locations":["myalgia","fatigue","thrombocytopenia","Nterminal"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1666138494281449473,"score":124.50105},{"pmid":32462267,"title":"Coronavirus Disease 2019 (COVID-19) and its implications for cardiovascular care: expert document from the German Cardiac Society and the World Heart Federation.","text":["Coronavirus Disease 2019 (COVID-19) and its implications for cardiovascular care: expert document from the German Cardiac Society and the World Heart Federation.","Coronavirus diseases 2019 (COVID-19) has become a worldwide pandemic affecting people at high risk and particularly at advanced age, cardiovascular and pulmonary disease. As cardiovascular patients are at high risk but also have dyspnea and fatigue as leading symptoms, prevention, diagnostics and treatment in these patients are important to provide adequate care for those with or without COVID-19 but most importantly when comorbid cardiovascular conditions are present. Severe COVID-19 with acute respiratory distress (ARDS) is challenging as patients with elevated myocardial markers such as troponin are at enhanced high risk for fatal outcomes. As angiotensin-converting enzyme 2 (ACE2) is regarded as the viral receptor for cell entry and as the Coronavirus is downregulating this enzyme, which provides cardiovascular and pulmonary protection, there is ongoing discussions on whether treatment with cardiovascular drugs, which upregulate the viral receptor ACE2 should be modified. As most of the COVID-19 patients have cardiovascular comorbidities like hypertension, diabetes, coronary artery disease and heart failure, which imposes a high risk on these patients, cardiovascular therapy should not be modified or even withdrawn. As cardiac injury is a common feature of COVID-19 associated ARDS and is linked with poor outcomes, swift diagnostic management and specialist care of cardiovascular patients in the area of COVID-19 is of particular importance and deserves special attention.","Clin Res Cardiol","Bohm, Michael","Frey, Norbert","Giannitsis, Evangelos","Sliwa, Karen","Zeiher, Andreas M","32462267"],"abstract":["Coronavirus diseases 2019 (COVID-19) has become a worldwide pandemic affecting people at high risk and particularly at advanced age, cardiovascular and pulmonary disease. As cardiovascular patients are at high risk but also have dyspnea and fatigue as leading symptoms, prevention, diagnostics and treatment in these patients are important to provide adequate care for those with or without COVID-19 but most importantly when comorbid cardiovascular conditions are present. Severe COVID-19 with acute respiratory distress (ARDS) is challenging as patients with elevated myocardial markers such as troponin are at enhanced high risk for fatal outcomes. As angiotensin-converting enzyme 2 (ACE2) is regarded as the viral receptor for cell entry and as the Coronavirus is downregulating this enzyme, which provides cardiovascular and pulmonary protection, there is ongoing discussions on whether treatment with cardiovascular drugs, which upregulate the viral receptor ACE2 should be modified. As most of the COVID-19 patients have cardiovascular comorbidities like hypertension, diabetes, coronary artery disease and heart failure, which imposes a high risk on these patients, cardiovascular therapy should not be modified or even withdrawn. As cardiac injury is a common feature of COVID-19 associated ARDS and is linked with poor outcomes, swift diagnostic management and specialist care of cardiovascular patients in the area of COVID-19 is of particular importance and deserves special attention."],"journal":"Clin Res Cardiol","authors":["Bohm, Michael","Frey, Norbert","Giannitsis, Evangelos","Sliwa, Karen","Zeiher, Andreas M"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32462267","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1007/s00392-020-01656-3","keywords":["corona","covid-19","cardiovascular risk","heart failure","hypertension","myocardial injury"],"topics":["Treatment","Mechanism","Diagnosis"],"weight":1,"_version_":1668079521332461569,"score":108.14063},{"pmid":32474135,"title":"Management of Cardiovascular Disease During Coronavirus Disease (COVID-19) Pandemic.","text":["Management of Cardiovascular Disease During Coronavirus Disease (COVID-19) Pandemic.","Patients with pre-existing cardiovascular disease and risk factors are more likely to experience adverse outcomes associated with the novel coronavirus disease-2019 (COVID-19). Additionally, consistent reports of cardiac injury and de novo cardiac complications, including possible myocarditis, arrhythmia, and heart failure in patients without prior cardiovascular disease or significant risk factors, are emerging, possibly due to an accentuated host immune response and cytokine release syndrome. As the spread of the virus increases exponentially, many patients will require medical care either for COVID-19 related or traditional cardiovascular issues. While the COVID-19 pandemic is dominating the attention of the healthcare system, there is an unmet need for a standardized approach to deal with COVID-19 associated and other traditional cardiovascular issues during this period. We provide consensus guidance for the management of various cardiovascular conditions during the ongoing COVID-19 pandemic with the goal of providing the best care to all patients and minimizing the risk of exposure to frontline healthcare workers.","Trends Cardiovasc Med","Ganatra, Sarju","Dani, Sourbha S","Shah, Sachin","Asnani, Aarti","Neilan, Tomas G","Lenihan, Daniel","Ky, Bonnie","Barac, Ana","Hayek, Salim S","Leja, Monika","Herrmann, Joerg","Thavendiranathan, Paaladinesh","Fradley, Michael","Bang, Vigyan","Shreyder, Katherine","Parikh, Rohan","Patel, Rushin","Singh, Amitoj","Brar, Simarjeet","Guha, Avirup","Gupta, Dipti","Mascari, Paolo","Patten, Richard","Venesy, David","Nohria, Anju","Resnic, Frederic S","32474135"],"abstract":["Patients with pre-existing cardiovascular disease and risk factors are more likely to experience adverse outcomes associated with the novel coronavirus disease-2019 (COVID-19). Additionally, consistent reports of cardiac injury and de novo cardiac complications, including possible myocarditis, arrhythmia, and heart failure in patients without prior cardiovascular disease or significant risk factors, are emerging, possibly due to an accentuated host immune response and cytokine release syndrome. As the spread of the virus increases exponentially, many patients will require medical care either for COVID-19 related or traditional cardiovascular issues. While the COVID-19 pandemic is dominating the attention of the healthcare system, there is an unmet need for a standardized approach to deal with COVID-19 associated and other traditional cardiovascular issues during this period. We provide consensus guidance for the management of various cardiovascular conditions during the ongoing COVID-19 pandemic with the goal of providing the best care to all patients and minimizing the risk of exposure to frontline healthcare workers."],"journal":"Trends Cardiovasc Med","authors":["Ganatra, Sarju","Dani, Sourbha S","Shah, Sachin","Asnani, Aarti","Neilan, Tomas G","Lenihan, Daniel","Ky, Bonnie","Barac, Ana","Hayek, Salim S","Leja, Monika","Herrmann, Joerg","Thavendiranathan, Paaladinesh","Fradley, Michael","Bang, Vigyan","Shreyder, Katherine","Parikh, Rohan","Patel, Rushin","Singh, Amitoj","Brar, Simarjeet","Guha, Avirup","Gupta, Dipti","Mascari, Paolo","Patten, Richard","Venesy, David","Nohria, Anju","Resnic, Frederic S"],"date":"2020-06-01T11:00:00Z","year":2020,"_id":"32474135","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.tcm.2020.05.004","keywords":["covid-19","sars-cov-2","cardiovascular disease","coronavirus"],"topics":["Treatment","Prevention"],"weight":1,"_version_":1668341932667961346,"score":107.737755},{"pmid":32292847,"pmcid":"PMC7151324","title":"The Heart in COVID19: Primary Target or Secondary Bystander?","text":["The Heart in COVID19: Primary Target or Secondary Bystander?","In the throes of the current COVID-19 pandemic, interest has burgeoned in the cardiovascular complications of this virulent viral infection. As troponin, a biomarker of cardiac injury, often rises in hospitalized patients, its interpretation and actionability require careful consideration. Fulminant myocarditis due to direct viral infection can certainly occur, but patients with increased oxygen demands due to tachycardia and fever, and reduced oxygen delivery due to hypotension and hypoxemia can cause myocardial injury indirectly. Cytokines released during the acute infection can elicit activation of cells within pre-existing atherosclerotic lesions, augmenting thrombotic risk and risk of ischemic syndromes. Moreover, microvascular activation by cytokines can cause not only myocardial injury but harm other organ systems commonly involved in COVID-19 infections including the kidneys. Dealing with the immense challenge of COVID-19 disease, confronted with severely ill patients in dire straits with virtually no rigorous evidence base to guide our therapy, we must call upon our clinical skills and judgment. These touchstones can help guide us in selecting patients who might benefit from the advanced imaging and invasive procedures that present enormous logistical challenges in the current context. Lacking a robust evidence base, pathophysiologic reasoning can help guide our choices of therapy for individual clinical scenarios. We must exercise caution and extreme humility, as often plausible interventions fail when tested rigorously. But act today we must, and understanding the multiplicity of mechanisms of myocardial injury in COVID-19 infection will help us meet our mission unsupported by the comfort of strong data.","JACC Basic Transl Sci","Libby, Peter","32292847"],"abstract":["In the throes of the current COVID-19 pandemic, interest has burgeoned in the cardiovascular complications of this virulent viral infection. As troponin, a biomarker of cardiac injury, often rises in hospitalized patients, its interpretation and actionability require careful consideration. Fulminant myocarditis due to direct viral infection can certainly occur, but patients with increased oxygen demands due to tachycardia and fever, and reduced oxygen delivery due to hypotension and hypoxemia can cause myocardial injury indirectly. Cytokines released during the acute infection can elicit activation of cells within pre-existing atherosclerotic lesions, augmenting thrombotic risk and risk of ischemic syndromes. Moreover, microvascular activation by cytokines can cause not only myocardial injury but harm other organ systems commonly involved in COVID-19 infections including the kidneys. Dealing with the immense challenge of COVID-19 disease, confronted with severely ill patients in dire straits with virtually no rigorous evidence base to guide our therapy, we must call upon our clinical skills and judgment. These touchstones can help guide us in selecting patients who might benefit from the advanced imaging and invasive procedures that present enormous logistical challenges in the current context. Lacking a robust evidence base, pathophysiologic reasoning can help guide our choices of therapy for individual clinical scenarios. We must exercise caution and extreme humility, as often plausible interventions fail when tested rigorously. But act today we must, and understanding the multiplicity of mechanisms of myocardial injury in COVID-19 infection will help us meet our mission unsupported by the comfort of strong data."],"journal":"JACC Basic Transl Sci","authors":["Libby, Peter"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32292847","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.jacbts.2020.04.001","topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138494517379072,"score":105.76434},{"pmid":32354733,"title":"SARS-CoV-2 pandemic and the cardiovascular system: What the non-cardiologist needs to know.","text":["SARS-CoV-2 pandemic and the cardiovascular system: What the non-cardiologist needs to know.","There has been the need to make major modifications to the way cardiology is practised in light of the COVID-19 pandemic. There has also been the need to recognise the complex cardiovascular manifestations and complications of COVID-19. In this article we provide guidance on the management of cardiac patients without COVID-19 in the current pandemic as well as patients with cardiac disease and COVID-19 and patients with cardiac complications of COVID-19. There is also a focus on indications and interpretation of commonly performed cardiac investigations in the setting of COVID-19. References are included from a number of specialist societies and groups.","Clin Med (Lond)","Davis, Gershan K","Adlan, Ahmed","Majewski, Jacek","Ibrahim, Bassem","32354733"],"abstract":["There has been the need to make major modifications to the way cardiology is practised in light of the COVID-19 pandemic. There has also been the need to recognise the complex cardiovascular manifestations and complications of COVID-19. In this article we provide guidance on the management of cardiac patients without COVID-19 in the current pandemic as well as patients with cardiac disease and COVID-19 and patients with cardiac complications of COVID-19. There is also a focus on indications and interpretation of commonly performed cardiac investigations in the setting of COVID-19. References are included from a number of specialist societies and groups."],"journal":"Clin Med (Lond)","authors":["Davis, Gershan K","Adlan, Ahmed","Majewski, Jacek","Ibrahim, Bassem"],"date":"2020-05-02T11:00:00Z","year":2020,"_id":"32354733","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.7861/clinmed.2020-0158","keywords":["covid-19","coronavirus","arrhythmias","chest infection","heart"],"weight":0,"_version_":1666138495159107586,"score":103.992096}]}